tbuckley/cabot-search huggingface dataset:
Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
Authors: Kimberly L. Blackwell, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do-Youn Oh, Veronique Dieras, Steven R. Olsen, Liang Fang, Michael W. Lu, Ellie Guardino, Sunil Verma
Journal: Journal of Clinical Oncology (2012)

LBA1 Background: T-DM1 is an antibody-drug conjugate comprising T, a stable linker, and the potent cytotoxic agent DM1; it incorporates the antitumor activities of T and the HER2-targeted delivery of DM1. Methods: EMILIA is a randomized study of T-DM1 vs XL, the only approved combination for T-refractory HER2+ MBC. Patients (pts) received T-DM1 (3.6 mg/kg IV q3w) or X (1000 mg/m 2 PO bid, days 1–14 q3w) + L (1,250 mg PO daily) until progressive disease (PD) or unmanageable toxicity. Pts had confirmed HER2+ MBC (IHC3+ and/or FISH+), and prior therapy with T and a taxane. Primary end points were PFS by independent review, OS and safety. An interim OS analysis (efficacy boundary: HR= 0.617; p=0.0003) was planned at the time of the final PFS analysis. Results: 991 pts were enrolled; 978 received treatment. Median (med) durations of follow-up were 12.9 (T-DM1) and 12.4 (XL) months (mo). Baseline demographics, prior therapy and disease characteristics were balanced. There was a significant improvement in PFS favoring T-DM1 (med 9.6 vs 6.4 mo; HR=0.650 [95% CI, 0.549–0.771]; p &lt;0.0001). The med T-DM1 OS was not reached vs 23.3 mo (HR=0.621 [95% CI, 0.475–0.813]; p=0.0005); the interim efficacy boundary was not crossed. T-DM1 was well tolerated with no unexpected safety signals. The most common grade ≥3 adverse events (AEs) per treatment were for T-DM1: thrombocytopenia (12.9% vs 0.2%), increased AST (4.3% vs 0.8%), and increased ALT (2.9% vs 1.4%); for XL: diarrhea (20.7% vs 1.6%), palmar plantar erythrodysesthesia (16.4% vs 0) and vomiting (4.5% vs 0.8%). The table lists other end points. Conclusions: T-DM1 conferred a significant and clinically meaningful improvement in PFS compared with XL. Other end points support T-DM1 as an active and well-tolerated novel therapy for HER2+ advanced BC. [Table: see text]
Autoradiographic Labeling of Pancreatic Acinar Cells with Thymidine-H3
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Access to health care for Hispanics
Authors: E. Ginzberg
Journal: JAMA (1991)

The conventional population paradigm in the United States has distinguished between the white majority and the sizable and easily identified black minority. Until recently, much less attention has been paid to Hispanics (or Latinos), currently 20 million in number, who the Census Bureau projects will increase to 31 million persons of a total population of 283 million by the year 2010. In the next two decades Hispanics will account for one of every three net additions to the US population. The analysis that follows considers the critical factors that collectively will determine the access of Hispanics to the health care system and illuminates the changes that, if introduced, will contribute to its improvement. These issues include the homogeneity or heterogeneity of the Hispanic population; the extent to which socioeconomic status adversely affects Hispanics' access to health care; the influence of demographic and epidemiological factors on their needs for care; the role of neighborhood factors in determining their access to the health and medical infrastructures; the paucity of Hispanic health professionals; and finally, the major reform proposals currently on the nation's health agenda as they relate to the issue of improved access to care for Hispanics. (<i>JAMA</i>. 1991;265:238-241)
Why Do Viruses in Bats Rarely Make Them Sick?
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Course in Medical uses of Radioactive Isotopes
Journal: JNCI Journal of the National Cancer Institute (1970)

Journal Article Course in Medical uses of Radioactive Isotopes Get access JNCI: Journal of the National Cancer Institute, Volume 44, Issue 1, January 1970, Page 233, https://doi.org/10.1093/jnci/44.1.233 Published: 01 January 1970
评估局部用补骨脂酚和视黄醇用于缓解面部光致老化的效果
Authors: S. Dhaliwal, I. Rybak, S.R. Ellis, M. Notay, M. Trivedi, W. Burney, A.R. Vaughn, M. Nguyen, P. Reiter, S. Bosanac, H. Yan, N. Foolad, R.K. Sivamani
Journal: British Journal of Dermatology (2019)

补骨脂酚主要存在于印度植物“补骨脂”(Psoralea corylifolia [babchi]) 的种子中,最近的研究表明,补骨脂酚具有多种抗氧化和抗炎特性。本研究由来自美国加利福尼亚、密歇根州、佛罗里达州和宾夕法尼亚州几所大学的研究人员开展,旨在对补骨脂酚与常用抗衰老物质“视黄醇”进行功效和副作用比较。44 名志愿者被要求在面部皮肤上每天两次涂抹 0.5% 的补骨脂酚乳膏或者每天一次涂抹 0.5% 的视黄醇乳膏,连续涂抹 12 周。此前的研究表明,0.5% 视黄醇可有效预防和消除皮肤衰老征兆,但会引起刺痛、起皮、发红等副作用。一台面部照相和分析系统用来在本研究第 0、4、8 和 12 周拍摄并分析高分辨率照片。患者也回答了有关副作用的问题。研究访视期间,一名皮肤病医生对色素沉着(皮肤着色)和发红体征进行了分级。为了避免发生偏倚,这名皮肤病医生对每位参加者当时使用哪种治疗并不知情。本研究发现,补骨脂酚和视黄醇都会显著缩小皱纹表面积并减少色素沉着过度,两种化合物之间不存在统计学意义上的差别。但视黄醇使用者报告起皮和皮肤刺痛的频率更高。上述结果在 12 周结束后最为明显,皱纹严重程度降低 20%。补骨脂酚组有 59% 的参加者在第 12 周时表现出色素沉着过度问题得到改善,相比之下,视黄醇组为 44%。这类改善与颜色强度和受影响面积均相关。本研究的结果表明,补骨脂酚有望成为一种副作用极小的有效抗衰老疗法,但这需要在更大规模的研究中进行证实。
Electron-Beam Computed Tomography for Evaluating Coronary Artery Disease
Authors: J. Paul Shields
Journal: Annals of Internal Medicine (1998)

Letters15 December 1998Electron-Beam Computed Tomography for Evaluating Coronary Artery DiseaseJ. Paul Shields, MDJ. Paul Shields, MDShields Coronary Artery Center; Spokane, WA 99204Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-12-199812150-00025 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In Dr. Fiorino's review on electron-beam CT [1], I believe it is unfortunate that no reference was made to data on this method compared with intracoronary ultrasonography. Coronary angiography is not the “gold standard.”References1. Fiorino AS. Electron-beam computed tomography, coronary artery calcium, and evaluation of patients with coronary artery disease. Ann Intern Med. 1998; 128:839-47. Google Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Shields Coronary Artery Center; Spokane, WA 99204 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 December 1998Volume 129, Issue 12Page: 1077KeywordsAngiographyComputed axial tomographyStable coronary artery diseaseUltrasound imaging Issue Published: 15 December 1998 CopyrightCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma
Authors: J. Mattes, K. Storm van's Gravesande, U. Reining, K. Alving, G. Ihorst, M. Henschen, J. Kuehr
Journal: European Respiratory Journal (1999)

Bronchial asthma is associated with increased levels of exhaled nitric oxide which are suppressible by glucocorticosteroid inhalation. Children with bronchial asthma were studied to elucidate the relation between endogenous NO release and recent symptoms of bronchial obstruction. Twenty-five children with atopic asthma and 11 healthy control subjects were enrolled and exhaled NO was studied using chemiluminescence analysis. The subjects breathed purified air (&lt;0.5 parts per billion (ppb) NO) exclusively through their mouths. Orally expired NO was measured during continuous nasal aspiration (1.3 L x min(-1)) to remove nasally produced NO. Nasal NO concentration was determined within the aspirated gas. Orally expired NO concentration was 2.5+/-0.3 ppb (mean +/-SEM) in healthy control subjects, 3.19+/-0.88 ppb (NS) in symptom-free children, and 8.28+/-0.81 ppb (p&lt; or =0.01) in children with bronchial asthma who had had recent symptoms of bronchial obstruction. Similarly, in the subgroup of children treated regularly with inhaled glucocorticosteroids those with recent symptoms had significantly higher orally exhaled NO concentrations than healthy control subjects (9.5+/-1.5 ppb, p&lt;0.05). The nasal NO concentration was 152.8+/-12.7 ppb in healthy control subjects and not significantly different in asthmatic children. In this group of asthmatic children, recent symptoms of bronchial obstruction were linked to significantly higher concentrations of NO in orally exhaled gas and to increased oral NO excretion rates. If substantiated by further studies, measurement of orally exhaled NO during nasal aspiration may become useful to monitor disease control in asthmatic children.
Dietary Fat and Breast Cancer
Authors: Walter Willett
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Dietary Fat and Breast Cancer Get access Walter Willett Walter Willett Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 14, 17 July 1991, Page 1035, https://doi.org/10.1093/jnci/83.14.1035 Published: 17 July 1991
Percutaneous placement of abdominal aortic stent grafts: Is there a role for intravascular ultrasound guidance? Marco T. Castagna, Neil J. Weissman, Gary S. Mintz, Michael Jaff, Nancy E. McCarthy, Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, John R. Laird. Washington Hospital Center, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
The Fly in Court
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine
Authors: Alexey Danilov, Habte A Yimer, Michael Boxer, John M Burke, Sunil Babu, Jia Li, Yong Mun, Peter C Trask, Anthony S Masaquel, Jeff P. Sharman
Journal: Blood (2019)
Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study
Authors: David J. Straus, Monika Dlugosz-Danecka, Joseph M. Connors, Árpád Illés, Marco Picardi, Ewa Lech-Marańda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Javier Munoz, Won Seog Kim, Ranjana Advani, Stephen M. Ansell, Anas Younes, Andrea Gallamini, Rachael Liu, Meredith Little, Keenan Fenton, Michelle A. Fanale, John A. Radford
Journal: Blood (2020)
Laval Médical, Quebec
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: ABC of Transfusion: Testing before transfusion, and blood ordering policies
Journal: BMJ (1990)

well tolerated by patients and are the most effective agents to date.If their long term safety is confirmed in large studies they are likely to become first line agents in the management of hypercholesterolaemia.They also have a role in patients with combined increases of cholesterol and triglyceride concentrations.Additional data on their impact on coronary morbidity and mortality are necessary, however, before the wide- spread use of statins is contemplated.OTHER DRUGS
Penis enlargement
Journal: BMJ (2005)

hours.The observation is not new, but the literature is not entirely consistent. 9 10To our knowledge, ours is the first prospective study to report such association.Of course, the reliability of information on exposure to environmental tobacco smoke in childhood can be questioned, although most people should be able to recall whether their parents smoked.The uptake of carcinogens in children exposed to environmental tobacco smoke is widespread and quantitatively important. 11 ConclusionsOur study contributes to the existing literature reinforcing the conclusions of the IARC Monograph Working Group 7 8 that there is sufficient evidence on the carcinogenicity of environmental tobacco smoke in humans.Mortality data for the Netherlands were obtained from Statistics Netherlands.
Die Medizin der Gegenwart in Selbstdarstellungen: Hoche: Kümmell: Marchand: Martius: Roux: Wiedersheim.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Visiting Physician in Berlin.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOT HEELS AS A CAUSE OF FLAT-FOOT
Authors: D. W. Samways
Journal: BMJ (1918)

<h3>BACKGROUND AND PURPOSE:</h3> No reliable MR imaging marker for the diagnosis of Menière disease has been reported. Our aim was to investigate whether the obliteration of the inferior portion of the vestibule and the contact with the stapes footplate by the vestibular endolymphatic space are reliable MR imaging markers in the diagnosis of Menière disease. <h3>MATERIALS AND METHODS:</h3> We retrospectively enrolled 49 patients, 24 affected by unilateral sudden hearing loss and 25 affected by definite Menière disease, who had undergone a 4-hour delayed 3D-FLAIR sequence. Two readers analyzed the MR images investigating whether the vestibular endolymphatic space bulged in the third inferior portion of the vestibule contacting the stapes footplate. This sign was defined as the vestibular endolymphatic space contacting the oval window. <h3>RESULTS:</h3> We analyzed 98 ears: 27 affected by Menière disease, 24 affected by sudden sensorineural hearing loss, and 47 that were healthy. The vestibular endolymphatic space contacting the oval window showed an almost perfect interobserver agreement (Cohen κ = 0.87; 95% CI, 0.69–1). The vestibular endolymphatic space contacting oval window showed the following: sensitivity = 81%, specificity = 96%, positive predictive value = 88%, and negative predictive value = 93% in differentiating Menière disease ears from other ears. The vestibular endolymphatic space contacting the oval window showed the following: sensitivity = 81%, specificity = 96%, positive predictive value = 96%, negative predictive value = 82% in differentiating Menière disease ears from sudden sensorineural hearing loss ears. <h3>CONCLUSIONS:</h3> The vestibular endolymphatic space contacting the oval window has high specificity and positive predictive value in differentiating Menière disease ears from other ears, thus resulting in a valid tool for ruling in Menière disease in patients with mimicking symptoms.
Abstract 4386: Androgen Receptor Requires JunD as a Co-activator to Switch on an Oxidative Stress Generation Pathway in Prostate Cancer Cells
Authors: Farideh Mehraein-Ghomi, Hirak S. Basu, Dawn R. Church, George Wilding
Journal: Cancer Research (2010)

Abstract The relatively high oxidative stress in the prostate is postulated to be one of the major factors for prostate carcinogenesis and prostate cancer (CaP) progression. We focused on elucidating metabolic pathways of oxidative stress generation in CaP cells. Previously, we have shown that the transcription factor JunD is essential for the androgen-induced reactive oxygen species (ROS) production in androgen-dependent LNCaP human prostate cancer cells. We have also recently demonstrated that androgen induces the first and the regulatory enzyme spermidine/spermine N1-acetyl transferase (SSAT) in a polyamine catabolic pathway that produces copious amounts of metabolic ROS. Here, we present co-immunoprecipitation and Gaussia luciferase reconstitution assay data that show that JunD forms a complex with activated AR in situ. Our chromatin immnoprecipitation (ChIP) assay data demonstrate that JunD binds directly with a specific SSAT promoter sequence only in androgen-treated LNCaP cells. Using a vector containing a luciferase reporter gene connected to the SSAT promoter and a JunD silenced LNCaP cell line, we show that JunD is an essential co-activator of androgen-induction of SSAT gene expression. As there is no Androgen Response Element (ARE) in the SSAT promoter, we hypothesize that JunD mediates binding of androgen-activated AR to the SSAT promoter for the induction of SSAT that leads to polyamine oxidation and ROS production in prostate cells. Elucidation of this pathway may help the design of inhibitors of oxidative stress generation specifically in prostate cells to prevent prostate cancer occurrence and progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4386.
The Human Intrinsic Factor-Vitamin B12 Receptor,Cubilin: Molecular Characterization and Chromosomal Mapping of the Gene to 10p Within the Autosomal Recessive Megaloblastic Anemia (MGA1) Region
Authors: Renata Kozyraki, Mette Kristiansen, Asli Silahtaroglu, Claus Hansen, Christian Jacobsen, Niels Tommerup, Pierre J. Verroust, Søren K. Moestrup
Journal: Blood (1998)